Buoyed by encouraging data for its lead drug for autosomal dominant polycystic kidney disease, Regulus Therapeutics has moved swiftly to file a financing that will give it the finances needed to accelerate its development.
The specialist in microRNA-directed medicines hopes to raise $100 million from the private placement, which is due to close later this week and would represent a sizeable cash injection for Regulus, which ended 2023 with cash reserves of around $24 million.
